Dublin, Feb. 07, 2019 (GLOBE NEWSWIRE) -- The "Global Gene Therapy Partnering Terms and Agreements 2010 to 2018" report has been added to ResearchAndMarkets.com's offering.

The Global Gene Therapy Partnering Terms and Agreements 2010-2018 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter gene Therapy Partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapytechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest gene therapy, oligonucletides including aptamers agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all gene therapy partnering deals announced since 2010 including financial terms where available including over 500 links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Highlights

• Trends in gene therapy partnering deals
• Disclosed headlines, upfronts, milestones and royalties by stage of development
• Gene Therapy Partnering contract documents
• Top gene therapy deals by value

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Gene therapy dealmaking

2.1. Introduction
2.2. Gene therapy partnering over the years
2.3. Most active Gene therapy dealmakers
2.4. Gene therapy partnering by deal type
2.5. Gene therapy partnering by therapy area
2.6. Deal terms for Gene therapy partnering
2.6.1 Gene therapy partnering headline values
2.6.2 Gene therapy deal upfront payments
2.6.3 Gene therapy deal milestone payments
2.6.4 Gene therapy royalty rates

Chapter 3 - Leading Gene therapy deals

3.1. Introduction
3.2. Top Gene therapy deals by value

Chapter 4 - Most active Gene therapy dealmakers

4.1. Introduction
4.2. Most active Gene therapy dealmakers
4.3. Most active Gene therapy partnering company profiles

Chapter 5 - Gene therapy contracts dealmaking directory

5.1. Introduction
5.2. Gene therapy contracts dealmaking directory

Chapter 6 - Gene therapy dealmaking by technology type

Chapter 7 - Partnering resource center

7.1. Online partnering
8.2. Partnering events
8.3. Further reading on dealmaking

Appendices

Appendix 1 - Gene therapy deals by company A-Z

Appendix 2 - Gene therapy deals by stage of development

Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

Appendix 3 - Gene therapy deals by deal type

Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Research
Spin out
Sub-license
Supply
Technology transfer

Appendix 4 - Gene therapy deals by therapy area

Cardiovascular
Central Nervous System
Genetic disorders
Hematology
Immunology
Infectives
Metabolic
Musculoskeletal
Obstetrics
Oncology
Ophthalmics
Orphan disease
Pediatrics
Respiratory

Appendix 5 - Deal type definitions

For more information about this report visit https://www.researchandmarkets.com/research/h7m3qr/global_gene?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Genomics

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.